Novel active substance launches vs Autoimmune cell therapy and T-cell engager trial starts
Novel active substance launches and Autoimmune cell therapy and T-cell engager trial starts: not enough published data yet to draw the two series side by side.
Change the pair
Compare different indicators
The series
Not enough published data to compare these two series yet
A comparison needs at least two observations of each indicator for the same region. Neither the global series nor any shared country reaches that yet. Each indicator's own page lists every record it has, with its source.
Provenance
Where these numbers come from
Novel active substance launches
Total number of novel active substances launched.
0 observations · source organisations: —
Autoimmune cell therapy and T-cell engager trial starts
Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
0 observations · source organisations: —
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring